Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax

PARSIPPANY, N.J., Dec. 2, 2020 -- (Healthcare Sales & Marketing Network) -- Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company's monoclonal antibody (mAb) anthrax antitoxin for the treat... Biopharmaceuticals, Regulatory Elusys Therapeutics, obiltoxaximab, anthrax
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news